GILEAD SCIENCES INC (GILD)
US3755581036 - Common Stock
GILEAD SCIENCES INC
NASDAQ:GILD (11/15/2024, 8:14:16 PM)
After market: 88.6 +0.2 (+0.23%)88.4
-3.71 (-4.03%)
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 18,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. The company is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The firm operates in more than 35 countries.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404
P: 16505743000
CEO: Daniel P. O'Day
Employees: 18000
Website: https://www.gilead.com/
GILD News
2 days ago - The Business JournalsGilead to see Bay Area layoffs in wake of Seattle office closing2 days ago - San Francisco ChronicleBiotech giant Gilead lays off 104 from Bay Area headquarters, including execsA slate of directors and vice presidents are among the layoffs.
2 days ago - Gilead Sciences, Inc.Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis3 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Gilead Sciences3 days ago - Zacks Investment ResearchBrokers Suggest Investing in Gilead (GILD): Read This Before Placing a BetAccording to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
3 days ago - Zacks Investment ResearchGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GILD Twits
Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
